SVB Securities analyst Christopher Liu maintained a Hold rating on Monte Rosa Therapeutics (GLUE – Research Report) on March 16 and set a price target of $15.00. The company’s shares opened today at $7.34.
According to TipRanks, Liu is an analyst with an average return of -19.1% and a 24.49% success rate. Liu covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Arvinas Holding Company, and Nurix Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monte Rosa Therapeutics with a $20.40 average price target, which is a 177.93% upside from current levels. In a report released on March 17, Credit Suisse also maintained a Hold rating on the stock with a $11.00 price target.
See the top stocks recommended by analysts >>
Based on Monte Rosa Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $27.32 million. In comparison, last year the company had a GAAP net loss of $23.44 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Read More on GLUE:
